News
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
FEATURED STORIES
As antibody-drug conjugates advance and move into earlier lines of treatment, drug developers have to build gentler therapies that don’t just extend survival but improve it.
FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
CRISPR Therapeutics reported in its first-quarter financials, as of March 31, it had $2.221 billion in cash, cash equivalents and marketable securities to drive its progress.
Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.
Pfizer made the splash of the young week Tuesday morning, inking an acquisition deal with New Haven, Connecticut-based Biohaven Pharma totaling $11.6 billion.
A recent study describes how researchers at the UK Research Institute at the University of Cambridge stumbled upon a potential target of dementia research.
In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.
OncoResponse is developing an innovative cancer therapy based upon antibodies produced by patients to components in the tumor microenvironment that regulate the immune response.
Janssen discontinued the development partnership due to advancements made by other companies against the human papillomavirus and its own changing strategic priorities.
Could big pharma buy out much of the biotech industry? Yes, according to analysts. But that’s not likely to happen anytime soon.
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.
Orion announced that it will be focusing on pain and oncology going forward. As a result, 32 working professionals within the company will be terminated, although six of those will be offered different positions.